Acceleron Pharma — ATS 2021 International Conference
40 slides from Acceleron Pharma's conference presentation, May 19, 2021
Slide 1: ATS 2021 International Conference Acceleron Investor and Analyst Call
A T S 2 0 21 I N T E R N A T I O N A L C O N F E R E N C E A C C E L E R O N I N V E S T O R A N D A N A L Y S T C A L L M A Y 1 9 , 2 0 2 1
Slide 2: Acceleron Forward-Looking Statements
Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS, including statements regarding the development and commercialization of sotatercept in pulmonary arterial hypertension (“PAH”) and of the Company’s oth
Slide 3: Habib Dable, Chief Executive Officer
H A B I B D A B L E C H I E F E X E C U T I V E O F F I C E R H AB IB DAB L E C H IEF EXEC U TI VE OF F I C ER This presentation is for investor relations purposes only – Not for product promotional purposes. 3
Slide 4: Our Vision for Sotatercept in Pulmonary Arterial Hypertension
Sotatercept is an investigational therapy that is not approved for any use in any country. Our Vision for Sotatercept in Pulmonary Arterial Hypertension (PAH) This presentation is for investor relations purposes only – Not for product promotional purposes. 4 BACKBONE THERAPY IN PAH
Slide 5: Jay Backstrom, Head of Research & Development
H A B I B D A B L E C H I E F E X E C U T I V E O F F I C E R J AY BAC KS TR OM , M D, M PH H E A D O F R E S E A R C H & D E V E L O P M E N T This presentation is for investor relations purposes only – Not for product promotional purposes. 5
Slide 6: Presentations at ATS 2021
Presentations at ATS 2021 This presentation is for investor relations purposes only – Not for product promotional purposes. 6 Sotatercept is an investigational therapy that is not approved for any use in any country. PULSAR Study Open-Label Extension: Interim Results from a Phase 2 Study of the Effi
Slide 7: ATS 2021 Presentation Highlights
ATS 2021 Presentation Highlights 7 Clinical Presentations: – PULSAR • Clinical efficacy was maintained or enhanced up through 48 weeks • Placebo crossover patients also achieved similar improvement in efficacy measures – SPECTRA • In this preliminary analysis of patients in the ongoing SPECTRA stu
Slide 8: Janethe Pena, Head of Pulmonary Medical Research
H A B I B D A B L E C H I E F E X E C U T I V E O F F I C E R J A NET HE P EN A , M D, P h D H E A D O F P U L M O N A R Y M E D I C A L R E S E A R C H This presentation is for investor relations purposes only – Not for product promotional purposes. 8
Slide 9: PULSAR study open-label extension: interim results
PULSAR study open-label extension: Interim results from a Phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH) David B. Badesch1, Simon R. Gibbs2, Mardi Gomberg-Maitland3, Marius M. Hoeper4, Vallerie McLaugh
Slide 10: Pulmonary arterial hypertension and sotatercept
Pulmonary arterial hypertension and sotatercept Sotatercept is an investigational product that is not approved for any use in any country. ActRIIA/B: activin receptor type 2A/B; ALK: activin receptor-like kinase; BMP: bone morphogenetic protein; BMPR-II: bone morphogenetic protein receptor type 2; G
Slide 11: PULSAR: Study design
6MWD: 6-minute walk distance; FC: functional class; NT-proBNP: N-terminal pro-brain natriuretic peptide; PAH: pulmonary arterial hypertension; PVR: pulmonary vascular resistance; SOC: standard of care; WHO: World Health Organization. 1. Humbert M, et al. N Engl J Med. 2021; 384: 1204–15. • A Phase 2
Slide 12: PULSAR: Change from baseline at week 24 and week 48
PULSAR: Change from baseline at week 24 and change from baseline at week 48 0 50 100-2000 -1000 0 1000 n=35 n=29 0 50 100 150 Continuing 0.7 mg/kg + SOC Continuing 0.3 mg/kg + SOC Placebo + SOC / 0.7 mg/kg + SOC Placebo + SOC / 0.3 mg/kg + SOC n=29 n=27 n=14 n=13 n=15 n=12 n=42 n=40 n=32 n=32 n=15 n
Slide 13: PULSAR: Overall safety experience including open-label extension
• As of the interim data cut, 103/106 (97%) patients reported treatment-emergent adverse events (TEAEs) • Serious TEAEs occurred in 30/106 (28%) patients • Overall, 9/106 (9%) patients had TEAEs that led to study discontinuation; 2/106 (2%) died (cardiac arrest, brain abscess) and deaths were not co
Slide 14: Conclusions
• In this first interim report from the open-label extension period of PULSAR, clinical efficacy was maintained or enhanced with sotatercept treatment across multiple study endpoints for up to 48 weeks • Improvements observed in patients re-randomized from the placebo group to sotatercept treatment
Slide 15: Acknowledgments
• We thank all the patients, their families, and all the PULSAR study investigators and coordinators who participated in the trial – PULSAR study investigators: Y. Adir, H. Alnuaimat, M. Andrade-Lima, J. Arakaki, R. Argula, A. Baloira, D. Baratz, J. Barberá, A. Bar-Shai, C. Berastegui, L. Bertoletti
Slide 16: Aaron Waxman, MD, PhD
A a r on Wax m a n, M D , P h D Director, Pulmonary Vascular Disease Program, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School Principal investigator in the SPECTRA trial and a paid consultant to Acceleron This presentation is for investor relations purposes only
Slide 17: The SPECTRA study: Phase 2a open-label exploratory study
Aaron B. Waxman1, Michael Risbano2, Robert Frantz3, Solaiappan Manimaran4, Jonathan Lu4, and Franz Rischard5 1Brigham and Women’s Hospital, Boston, MA; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Mayo Clinic, Rochester, NY; 4Acceleron Pharma, Cambridge, MA; 5University of Arizona, Tuc
Slide 18: Disclosure to learners
Disclosure to learners Company name: Type of relationship: Acceleron Research support/Consultant Financial relationships with relevant companies within the past 24 months:
Slide 19: SPECTRA: Study design
Inclusion criteria • WHO PH Group I (PAH) • WHO Functional Class III • Right heart catheterization with PVR ≥4 Wood units • 6-minute walk distance (6MWD) 100–550 m • Stable combination PAH therapy Open-label treatment period (24 weeks) Cycle 1: Sotatercept 0.3 mg/kg + SOC (n=21) Cycle 2 onward: Sota
Slide 20: SPECTRA: Baseline characteristics
Total patients enrolled n=21 Evaluable patients at week 24 n=10 Female, n (%) 17 (81) 6 (60) Age, median (range), years 44 (21–70) 45 (25–66) Time since diagnosis, median (range), years 4.9* (0.6–15.0) 3.2 (0.6–13.1) PAH classification, n (%) Idiopathic 13 (62) 5 (50) Heritable 1 (5) 1 (10) Associat
Slide 21: SPECTRA: Supine resting hemodynamics
Supine resting Baseline n=10 Week 24 n=10 Mean change at week 24 n=10 PVR, dynes-sec/cm5 576.4 (139.2) 369.2 (121.1) -207.3 (146.4) mPAP, mmHg 43.4 (9.7) 30.6 (9.7) -12.8 (7.1) PAWP, mmHg 10.0 (4.0) 9.1 (4.8) -0.9 (3.4) Cardiac output, L/min 4.7 (0.7) 4.8 (1.4) 0.1 (1.4) SPECTRA: Supine resting hemo
Slide 22: SPECTRA study: iCPET assessments
SPECTRA study: iCPET assessments Primary endpoint: Change from baseline in peak oxygen uptake (VO2 max) at 24 weeks Secondary endpoints from iCPET measured as change from baseline at 24 weeks: – Ventilatory efficiency (VE/VCO2 slope) – Cardiac index (L/min/m2) – Mean pulmonary artery pressure, (
Slide 23: Why iCPET?
Why iCPET? Affords the dynamic and simultaneous assessment of cardiovascular, respiratory, and metabolic function during exercise iCPET informs clinicians regarding the pathophysiologic basis of dyspnea to provide a definitive diagnosis, even in patients with comorbid cardiovascular and pulmonar
Slide 24: How Do We Perform iCPET?
How Do We Perform iCPET? VO, and VCO, ca0, Arterial oxygen content co, Venous oxygen content 24 | 2-min unloaded eyeling Rest hour post peak BRIGHAM HEALTH BRIGHAM AND WOMEN'S HOSPITAL HARVARD MEDICAL SCHOOL
Slide 25: SPECTRA Study: Case Report of First Patient (1/2)
SPECTRA Study: Case Report of First Patient (1/2) 25 • 25-year-old female, idiopathic PAH for 4.7 years, receiving tadalafil and ambrisentan for the treatment of PAH. At baseline, subject was classified as WHO FC III and 6MWD was 285.5 m. • The subject’s medical history includes gastroesophageal ref
Slide 26: SPECTRA Study Case Report of First Patient (2/2)
26 SPECTRA Study Case Report of First Patient (2/2) Peak Exercise Hemodynamics (iCPET) Baseline Week 24 Week 48 Work, W 39 66 85 mPAP, mmHg 41 27 23 TPG, mmHg 37 25 22 PAWP, mmHg 4 2 1 CO, L/min 7.0 7.84 7.4 PVR, dynes-sec/cm5 423 255 237 Pulmonary artery compliance, mL/mmHg 2.2 3.9 2.3 VO2 max, mL/
Slide 27: SPECTRA: Peak exercise measures and 6-minute walk distance
Peak exercise Baseline n=10 Week 24 n=10 Mean change at week 24 n=10 VO2 max, mL/min/kg 12.7 (3.5) 14.0 (4.4) 1.27 (2.6) VE/VCO2 slope 50.7 (25.8) 41.2 (13.1) -9.5 (15.7) Ca-vO2, mL/100 mL 9.7 (2.1)* 11.5 (3.2)* 1.4 (2.1)† Workload, W 72.3 (34.0) 88.5 (37.6) 16.2 (13.0) mPAP, mmHg 66.8 (14.3) 55.2 (
Slide 28: SPECTRA: Safety
n (%) n=21 TEAEs 16 (76) Serious TEAEs 3 (14) Serious related TEAEs 0 (0) TEAEs of special interest* 0 (0) TEAEs leading to treatment discontinuation 1 (5)^ TEAEs leading to death 0 (0) SPECTRA: Safety Interim analysis data cut-off date:25 February 2021. *TEAEs of special interest defined as any adv
Slide 29: Conclusions
Conclusions 6MWD: 6-minute walk distance; iCPET: invasive cardiopulmonary exercise testing; PAH: pulmonary arterial hypertension. 1. ClinicalTrials.gov. A study of sotatercept for the treatment of pulmonary arterial hypertension (STELLAR). https://clinicaltrials.gov/ct2/show/NCT04576988 [Accessed 24
Slide 30: Acknowledgments
Acknowledgments • We thank all the patients, their families, and all the SPECTRA study investigators and coordinators who participated in the trial – SPECTRA study investigators: Aaron B. Waxman, MD, PhD, Franz Rischard, MD, Michael Risbano, MD, and Robert Frantz, MD • The study was sponsored by Acc
Slide 31: Jay Backstrom, Head of Research & Development
H A B I B D A B L E C H I E F E X E C U T I V E O F F I C E R J AY BAC KS TR OM , M D, M PH H E A D O F R E S E A R C H & D E V E L O P M E N T This presentation is for investor relations purposes only – Not for product promotional purposes. 31
Slide 32: ATS 2021 Key Takeaways
ATS 2021 Key Takeaways This presentation is for investor relations purposes only – Not for product promotional purposes. 32 Week 48 PULSAR data reinforces the efficacy of sotatercept across multiple endpoints – Sustained and further improvement in 6MWD with consistent and reproducible improvement
Slide 33: STELLAR Phase 3 Study of Sotatercept in PAH
33 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH ENROLLING This presentation is for investor relations purposes only – Not
Slide 34: Key Inclusion Criteria for PULSAR Relative to STELLAR Phase 3 Trial
Key Inclusion Criteria for PULSAR Relative to STELLAR Phase 3 Trial 34 WHO: World Health Organization; RHC: right heart catheterization; PVR: Pulmonary vascular resistance. Key Inclusion criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class II or III • Baseline RHC with PVR ≥5 Woo
Slide 35: STELLAR Phase 3 Trial Design Schema
STELLAR Phase 3 Trial Design Schema 35 Randomization 1:1 Stratified by WHO FC and Background therapy Double-Blind Primary treatment period (24 weeks) Placebo + background PAH therapy (mono, double, or triple) N = 142 Sotatercept 0.3 mg/kg first dose to 0.7 mg/kg Q21 days + background PAH therapy (mo
Slide 36: Sotatercept Phase 3 Clinical Development Plan and Vision
L A B E L E X PA N S I O NR E G I S T R AT I O N A L S O TAT E R C E P T V I S I O N Main Phase 3 Study Phase 3 Newly Diagnosed Intermediate and High-Risk Patient Study Phase 3 WHO Functional Class III/IV at High Risk of Mortality Study ZENITH BACKBONE THERAPY IN PAH Sotatercept Phase 3 Clinical Dev
Slide 37: R&D Day 2021 Save the Date
R&D Day 2021 37 S A V E T H E D A T E R&D Day 2021 June 22nd, 2021 This presentation is for investor relations purposes only – Not for product promotional purposes.
Slide 38: ATS 2021 Q&A Session
ATS 2021 Q&A Session This presentation is for investor relations purposes only – Not for product promotional purposes. 38 HABIB DABLE Chief Executive Officer JAY T. BACKSTROM, MD, MPH Head of Research & Development JANETHE PENA, MD, PHD Head of Pulmonary Medical Research TODD JAMES SVP, Corporate Af
Slide 39: Appendix
— 7 — > ACCELERON =~ APPENDIX
Slide 40: Upcoming and Ongoing Corporate Priorities for Pulmonary Programs
Upcoming and Ongoing Corporate Priorities for Pulmonary Programs Sotatercept – STELLAR Phase 3 trial enrollment and execution – HYPERION Phase 3 trial planned start by 2H:2021 – ZENITH Phase 3 trial expected initiation by 2H:2021 – PULSAR open-label extension trial completion – SPECTRA Phase 2 tri